(a) the amino acid sequence (SEQ ID NO:1)

D-V-N-Y-A-F-L-H-A-T-D-L-L-P-A-C-D-G-E-R,

(b) the amino acid sequence (SEQ ID NO:2)

S-N-M-Y-A-M-M-I-A-R-F-K-M-F-P-E-V-K-E-K,

(c) the amino acid sequence (SEQ ID NO:3),

N-W-E-L-A-D-Q-P-Q-N-L-E-E-I-L-M-H-C-Q-T,

(d) the amino acid sequence (SEQ ID NO:4)

T-L-K-Y-A-I-K-T-G-H-P-R-Y-F-N-Q-L-S-T-G,

(5) the amino acid sequence (SEQ ID NO:5)

P-R-Y-F-N-Q-L-S-T-G-L-D-M-V-G-L-A-A-D-W,

(f) the amino acid sequence (SEQ ID NO:6)

T-Y-E-I-A-P-V-F-V-L-L-E-Y-V-T-L-K-K-M-R,

(g) the amino acid sequence (SEQ ID NO:7)

F-F-R-M-V-I-S-N-P-A-A-T-H-Q-D-I-D-F-L-I, wherein the peptide or peptide derivative of SEQ ID NO. 7 comprises a C-terminal isoleucine residue,

(h) a partial region of the amino acid sequence shown in (a), (b), (c), (d), (e), (f) and/or (g) with a length of at least 6 amino acids,

and/or

(i) an amino acid sequence which has an equivalent specificity and/or binding affinity to human MHC molecules as the amino acid sequence shown in (a), (b), (c), (d), (e), (f), (g) and/or (h);

wherein said peptide or peptide derivative has a length of up to 25 amino acids.